Seroprotection Against Mumps in MMR Vaccinated Children Aged 9–12 Years: A Cross-Sectional Study
Indian Pediatrics · 2026-09 · 63 (9) · 669-673
DOI: 10.1007/s13312-026-00406-4 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Indian Pediatrics, online erschienen am 30.07.2026. Verfasst von Dhairya Bansal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India. Hauptthemen laut MEDLINE: Measles-Mumps-Rubella Vaccine, Mumps, Antibodies, Viral. Die Arbeit nennt 19 Literaturangaben. Gefördert von: University College of Medical Sciences.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
To estimate the proportion of children aged 9–12 years with seroprotective antibody titers against mumps following a single dose of measles–mumps–rubella (MMR) vaccine administered in early childhood, and to explore the association between seroprotection and clinicodemographic profile.
Methods
A cross-sectional study was conducted at a tertiary hospital in Delhi between April 2024 and August 2025. Children aged 9–12 years with a documented receipt of a single dose of MMR vaccine at 16–24 months of age were recruited. Two mL of venous blood was collected and analyzed for serum mumps-specific IgG antibodies using enzyme-linked immunosorbent assay (ELISA), with seroprotection defined as mumps antibody titers ≥ 22 RU/mL. The association between seroprotection and demographic and clinical variables, including age, sex, age at vaccination, and nutritional status, was assessed using the chi-square test or Fisher’s exact test.
Results
Eighty-six children (48% males) aged 9–12 years [mean (SD) 10.35 (1.04) years] were enrolled. Overall, 84.8% demonstrated seroprotective antibody titers against mumps. The median (q1, q3) mumps-specific IgG titer was 97.6 (46.1, 144.9) RU/mL. Children aged > 10 years were significantly more likely to be seronegative compared to younger children (OR 3.99, 95% CI 1.07, 14.92, P = 0.039).
Conclusion
Nearly 85% of children who had received a single MMR dose at 16–24 months of age had seroprotective mumps antibody titers at 9–12 years. The findings highlight the need for larger community-based studies on the durability of mumps immunity and add to the accumulating evidence informing future MMR vaccination strategies in India.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India.
- Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India. draaradhanasingh@gmail.com.
- Department of Microbiology, University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India.
Förderung
- University College of Medical Sciences
Zitieren
APA
Bansal, D., Aaradhana, Kashyap, B., Aggarwal, A., & Banik, D. (2026). Seroprotection Against Mumps in MMR Vaccinated Children Aged 9–12 Years: A Cross-Sectional Study. Indian Pediatrics, 63(9), 669-673. https://doi.org/10.1007/s13312-026-00406-4
Vancouver
Bansal D, Aaradhana, Kashyap B, Aggarwal A, Banik D. Seroprotection Against Mumps in MMR Vaccinated Children Aged 9–12 Years: A Cross-Sectional Study. Indian Pediatrics. 2026;63(9):669-673. doi:10.1007/s13312-026-00406-4
BibTeX
@article{Bansal2026,
author = {Bansal, Dhairya and Aaradhana and Kashyap, Bineeta and Aggarwal, Anju and Banik, Debamita},
title = {Seroprotection Against Mumps in MMR Vaccinated Children Aged 9–12 Years: A Cross-Sectional Study},
journal = {Indian Pediatrics},
year = {2026},
volume = {63},
number = {9},
pages = {669--673},
doi = {10.1007/s13312-026-00406-4}
}
EUVIMED